Extended-releaseoralminoxidil (VDPHL01) shows promising results for hair growth with improved safety, achieving significant hair count increases and minimal side effects compared to placebo. The treatment is designed to maintain effective concentrations while reducing side effects, making it a safer option for those who cannot tolerate standard minoxidil.
Veradermics' extended-releaseoralminoxidil is expected to be commercially available in 2027-2028, while another company, Minx, may release a similar product sooner. VDPHL01 is considered more clinically validated compared to Minx.
A participant using VeradermicsVDPHL01, an extended-releaseoralminoxidil, experienced significant hair regrowth from Norwood 6 to Norwood 3V without side effects. They plan to use dutasteride after the treatment to maintain results.
Veradermics' new hair loss treatment, VDPHL01, is likely a modified releaseoralminoxidil, which has received $75 million in funding for clinical trials. Despite skepticism about investing in a known treatment, some believe it could offer improved efficacy and reduced side effects.
This study reviews new treatments for androgenetic alopecia, including cell-derived exosomes and investigational drugs, which show potential to improve hair density and quality but require more rigorous and standardized trials to confirm efficacy and safety.
2 citations
,
January 2009 in “Journal of Drug Delivery Science and Technology”
This study found that cationic vesicles enhanced minoxidil skin retention and in vivo hair growth efficacy compared to other formulation types due to electrostatic interactions with the skin.
An essential vasodilator with some anti-androgenic effects
Minoxidil 2%, 5% and 10% which is better to use?In a randomized trial in men, 5% topical minoxidil produced more hair growth than 2%. There is no approved 10% product and no head-to-head trial showing it beats 5%; higher strengths mainly add irritation and systemic absorption. Approved strengths differ by sex, so check the label for your product.
From hypertension to hair: the unexpected story of minoxidilMinoxidil was developed as an oral blood-pressure drug and approved as Loniten in 1979; unwanted hair growth in patients led to topical Rogaine, approved for men in 1988 and for women in 1991. Trials support topical minoxidil for pattern hair loss, while low-dose oral minoxidil is a prescription drug used off-label and needs medical supervision.